Combination therapy for the treatment of tumors
View Patent ↗The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.
1. A combination of anti-gastrin-dependent tumor therapeutic ingredients, comprising:
(i) an anti-gastrin G17 immunogen, wherein the anti-gastrin G17 immunogen comprises a peptide that has the sequence of amino acid residues pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu as set forth in SEQ ID NO: 1; and
(ii) one or more cytotoxic chemotherapeutic agents.
2. The combination of claim 1 , wherein the anti-gastrin G17 immunogen comprises a therapeutically effective amount of the peptide.
3. The combination of claim 2 , wherein the anti-gastrin G17 immunogen is conjugated to a Diphtheria toxoid.
4. The combination of claim 2 , wherein the anti-gastrin G17 immunogen comprises the peptide that has the sequence of amino acid residues as set forth in SEQ ID NO: 1, a protein carrier, and a spacer peptide that links the peptide that has the sequence of amino acid residues as set forth in SEQ ID NO: 1 to the carrier.
5. The combination of claim 2 , wherein the one or more cytotoxic chemotherapeutic agents are selected from the group consisting of 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor, and proglumide.
6. The combination of claim 1 , wherein each of the anti-gastrin G17 immunogen and the one or more cytotoxic chemotherapeutic agents comprises a pharmaceutically acceptable carrier.
7. The combination of claim 1 , wherein the anti-gastrin G17 immunogen and the one or more cytotoxic chemotherapeutic agents are in separate compositions.
8. The combination of claim 1 , wherein the anti-gastrin G17 immunogen and the one or more cytotoxic chemotherapeutic agents are formulated in the same composition.
9. A method of treatment of a gastrin-dependent tumor, comprising administering to a patient in need thereof the components of the combination of claim 1 to thereby treat the gastrin-dependent tumor in the patient.
10. The method of claim 9 , wherein the peptide is conjugated to a diphtheria toxoid carrier.
11. The method of claim 9 , wherein the anti-gastrin G17 immunogen comprises the peptide, a protein carrier, and a spacer peptide that projects the peptide away from the protein carrier and enhances capacity of the peptide to bind lymphocyte receptors.
12. The method of claim 9 , wherein the one or more cytotoxic chemotherapeutic agents are selected from the group consisting of 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor, and proglumide.
13. The method of claim 9 , wherein the cytotoxic chemotherapeutic agent is 5-fluorouracil or leucovorin.
14. The method of claim 13 , wherein the anti-gastrin-17 immunogen is administered prior to administration of the one or more cytotoxic chemotherapeutic agents.
15. The method of claim 9 , wherein the anti-gastrin-17 immunogen is administered prior to administration of the one or more chemotherapeutic agents.
16. The method of claim 9 , wherein the one or more cytotoxic chemotherapeutic agents are administered in several cycles.